Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $42,500.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $8.50, for a total value of $42,500.00. Following the completion of the sale, the insider owned 1,356,053 shares in the company, valued at $11,526,450.50. The trade was a 0.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total value of $42,500.00.
• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.52, for a total value of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total value of $147,900.00.

Xeris Biopharma Trading Up 0.1%

NASDAQ XERS opened at $8.59 on Friday. Xeris Biopharma Holdings, Inc. has a 12 month low of $5.25 and a 12 month high of $10.08. The stock has a market cap of $1.57 billion, a P/E ratio of -78.09 and a beta of 0.70. The stock’s fifty day moving average price is $8.39 and its 200-day moving average price is $6.97. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). The company had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. As a group, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Walleye Capital LLC purchased a new stake in Xeris Biopharma during the second quarter valued at $4,841,000. Rice Hall James & Associates LLC purchased a new position in Xeris Biopharma in the first quarter worth about $1,456,000. Janus Henderson Group PLC boosted its position in Xeris Biopharma by 322.8% in the first quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock worth $1,713,000 after purchasing an additional 225,602 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Xeris Biopharma during the 2nd quarter valued at about $1,007,000. Finally, Granahan Investment Management LLC grew its stake in shares of Xeris Biopharma by 249.4% during the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock valued at $9,604,000 after purchasing an additional 873,236 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on XERS shares. Barclays raised their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $12.00.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.